 Ashoke Khanwalkar
Concepts (123)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Paranasal Sinuses | 4 | 2023 | 80 | 2.400 |
Why?
| | Nasal Surgical Procedures | 3 | 2023 | 6 | 2.240 |
Why?
| | Rhinitis | 6 | 2025 | 158 | 1.570 |
Why?
| | Tranexamic Acid | 2 | 2023 | 40 | 1.560 |
Why?
| | Sinusitis | 5 | 2025 | 221 | 1.330 |
Why?
| | Endoscopy | 5 | 2024 | 318 | 1.320 |
Why?
| | Lymphatic Abnormalities | 2 | 2020 | 19 | 1.220 |
Why?
| | Nasal Obstruction | 3 | 2022 | 27 | 1.070 |
Why?
| | Nose Diseases | 2 | 2021 | 13 | 0.910 |
Why?
| | Nasal Polyps | 1 | 2024 | 59 | 0.850 |
Why?
| | Antifibrinolytic Agents | 1 | 2023 | 51 | 0.770 |
Why?
| | Telangiectasia, Hereditary Hemorrhagic | 1 | 2022 | 13 | 0.750 |
Why?
| | Biological Products | 1 | 2024 | 216 | 0.700 |
Why?
| | Olfaction Disorders | 4 | 2025 | 63 | 0.670 |
Why?
| | Otorhinolaryngologic Surgical Procedures | 1 | 2020 | 40 | 0.650 |
Why?
| | Neck | 1 | 2020 | 101 | 0.640 |
Why?
| | Hydrocodone | 1 | 2018 | 17 | 0.600 |
Why?
| | Dyspnea | 1 | 2020 | 254 | 0.570 |
Why?
| | Mesothelioma | 2 | 2015 | 44 | 0.570 |
Why?
| | Intubation, Intratracheal | 1 | 2020 | 257 | 0.560 |
Why?
| | Cystic Fibrosis | 5 | 2025 | 1114 | 0.540 |
Why?
| | Betacoronavirus | 1 | 2020 | 270 | 0.540 |
Why?
| | Postoperative Complications | 2 | 2020 | 2654 | 0.530 |
Why?
| | Pain, Postoperative | 1 | 2018 | 265 | 0.500 |
Why?
| | Smell | 4 | 2025 | 117 | 0.490 |
Why?
| | Acetaminophen | 1 | 2018 | 268 | 0.490 |
Why?
| | Inpatients | 1 | 2020 | 500 | 0.490 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 350 | 0.480 |
Why?
| | Respiratory Tract Infections | 1 | 2020 | 390 | 0.480 |
Why?
| | Respiration, Artificial | 1 | 2020 | 645 | 0.480 |
Why?
| | Pleural Neoplasms | 1 | 2015 | 25 | 0.480 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 373 | 0.460 |
Why?
| | Coronavirus Infections | 1 | 2020 | 364 | 0.460 |
Why?
| | Patient Reported Outcome Measures | 1 | 2018 | 402 | 0.460 |
Why?
| | Epistaxis | 2 | 2023 | 12 | 0.390 |
Why?
| | Aminophenols | 2 | 2024 | 156 | 0.370 |
Why?
| | Turbinates | 2 | 2022 | 14 | 0.370 |
Why?
| | Analgesics, Opioid | 1 | 2018 | 1000 | 0.340 |
Why?
| | Chronic Disease | 6 | 2025 | 1793 | 0.320 |
Why?
| | Telemedicine | 1 | 2018 | 862 | 0.320 |
Why?
| | Quality of Life | 5 | 2025 | 2892 | 0.300 |
Why?
| | Humans | 23 | 2025 | 137585 | 0.250 |
Why?
| | Benzodioxoles | 2 | 2024 | 115 | 0.240 |
Why?
| | Goldenhar Syndrome | 1 | 2025 | 11 | 0.240 |
Why?
| | Cranial Fossa, Middle | 1 | 2025 | 15 | 0.240 |
Why?
| | Drug Combinations | 3 | 2024 | 343 | 0.240 |
Why?
| | Treatment Outcome | 5 | 2024 | 10811 | 0.240 |
Why?
| | Fistula | 1 | 2025 | 47 | 0.230 |
Why?
| | Intracranial Hypotension | 1 | 2025 | 56 | 0.220 |
Why?
| | Omalizumab | 1 | 2024 | 51 | 0.220 |
Why?
| | Minimal Clinically Important Difference | 1 | 2023 | 16 | 0.220 |
Why?
| | Food Preferences | 1 | 2025 | 119 | 0.210 |
Why?
| | Indoles | 2 | 2024 | 412 | 0.210 |
Why?
| | Prospective Studies | 7 | 2025 | 7604 | 0.200 |
Why?
| | Platelet-Rich Plasma | 1 | 2022 | 32 | 0.190 |
Why?
| | Blood Loss, Surgical | 1 | 2023 | 101 | 0.190 |
Why?
| | Cautery | 1 | 2022 | 4 | 0.190 |
Why?
| | Lung Neoplasms | 1 | 2015 | 2526 | 0.190 |
Why?
| | Bevacizumab | 1 | 2022 | 138 | 0.180 |
Why?
| | Vibration | 1 | 2021 | 72 | 0.180 |
Why?
| | Nasal Cavity | 1 | 2021 | 52 | 0.170 |
Why?
| | Rhinoplasty | 1 | 2021 | 29 | 0.170 |
Why?
| | Seroma | 1 | 2020 | 3 | 0.170 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2022 | 545 | 0.150 |
Why?
| | Return to Work | 1 | 2018 | 21 | 0.150 |
Why?
| | Visual Analog Scale | 1 | 2018 | 33 | 0.150 |
Why?
| | Hypersensitivity | 1 | 2022 | 257 | 0.150 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2024 | 804 | 0.150 |
Why?
| | Double-Blind Method | 1 | 2023 | 1993 | 0.140 |
Why?
| | Operative Time | 1 | 2018 | 145 | 0.140 |
Why?
| | Retrospective Studies | 3 | 2020 | 15657 | 0.140 |
Why?
| | Tumor Burden | 2 | 2015 | 309 | 0.130 |
Why?
| | Female | 10 | 2025 | 73304 | 0.130 |
Why?
| | Tertiary Care Centers | 1 | 2018 | 160 | 0.130 |
Why?
| | Male | 9 | 2025 | 67762 | 0.130 |
Why?
| | Middle Aged | 7 | 2025 | 33479 | 0.120 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1477 | 0.110 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2015 | 153 | 0.110 |
Why?
| | Child, Preschool | 2 | 2020 | 11074 | 0.110 |
Why?
| | Positron-Emission Tomography | 1 | 2015 | 294 | 0.110 |
Why?
| | Tomography, X-Ray Computed | 3 | 2025 | 2691 | 0.100 |
Why?
| | Surveys and Questionnaires | 5 | 2025 | 5778 | 0.100 |
Why?
| | Adult | 7 | 2025 | 37929 | 0.100 |
Why?
| | Quinolones | 2 | 2024 | 137 | 0.090 |
Why?
| | Ambulatory Care Facilities | 1 | 2014 | 232 | 0.090 |
Why?
| | Length of Stay | 1 | 2018 | 1215 | 0.090 |
Why?
| | Mentors | 1 | 2014 | 202 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1639 | 0.090 |
Why?
| | Education, Medical, Undergraduate | 1 | 2014 | 188 | 0.090 |
Why?
| | Follow-Up Studies | 1 | 2020 | 5131 | 0.090 |
Why?
| | Pyridines | 2 | 2024 | 506 | 0.080 |
Why?
| | Time Factors | 1 | 2020 | 6828 | 0.080 |
Why?
| | Students, Medical | 1 | 2014 | 348 | 0.080 |
Why?
| | Child | 2 | 2020 | 21935 | 0.080 |
Why?
| | Clinical Competence | 1 | 2014 | 1118 | 0.060 |
Why?
| | Infant | 1 | 2020 | 9465 | 0.060 |
Why?
| | Risk Factors | 1 | 2020 | 10388 | 0.060 |
Why?
| | Aged | 3 | 2021 | 23961 | 0.060 |
Why?
| | Pyrrolidines | 1 | 2023 | 79 | 0.050 |
Why?
| | Social Class | 1 | 2024 | 282 | 0.050 |
Why?
| | Nose | 1 | 2022 | 67 | 0.050 |
Why?
| | Ribs | 1 | 2021 | 35 | 0.040 |
Why?
| | Patient Health Questionnaire | 1 | 2021 | 37 | 0.040 |
Why?
| | Adolescent | 1 | 2020 | 21513 | 0.040 |
Why?
| | Syndrome | 1 | 2021 | 358 | 0.040 |
Why?
| | Pyrazoles | 1 | 2023 | 423 | 0.040 |
Why?
| | Postoperative Period | 1 | 2021 | 342 | 0.040 |
Why?
| | Cadaver | 1 | 2021 | 296 | 0.040 |
Why?
| | Cartilage | 1 | 2021 | 188 | 0.040 |
Why?
| | Cost of Illness | 1 | 2022 | 308 | 0.040 |
Why?
| | Consensus | 1 | 2022 | 683 | 0.040 |
Why?
| | Sex Factors | 1 | 2024 | 2071 | 0.040 |
Why?
| | Young Adult | 2 | 2024 | 13209 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2021 | 7635 | 0.030 |
Why?
| | Volunteers | 1 | 2014 | 29 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2025 | 5472 | 0.030 |
Why?
| | Lymphatic Metastasis | 1 | 2015 | 352 | 0.030 |
Why?
| | Animals | 1 | 2015 | 36940 | 0.020 |
Why?
| | Peer Group | 1 | 2014 | 242 | 0.020 |
Why?
| | Neoplasm Staging | 1 | 2015 | 1389 | 0.020 |
Why?
| | Interpersonal Relations | 1 | 2014 | 397 | 0.020 |
Why?
| | Program Evaluation | 1 | 2014 | 898 | 0.020 |
Why?
| | Logistic Models | 1 | 2014 | 2074 | 0.020 |
Why?
|
|
Khanwalkar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|